FindTrial
Sign In

Conbercept and Triamcinolone Acetonide for Macular Edema Secondary to Retinal Vein Occlusion

Comparison of Intravitreal Injection of Conbercept and Triamcinolone Acetonide for Macular Edema Secondary to Retinal Vein Occlusion

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900028003
Enrollment
Unknown
Registered
2019-12-08
Start date
2017-06-12
Completion date
Unknown
Last updated
2019-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinal vein occlusion

Interventions

B-IVC/B-IVTA:intravitreal injection of conbercept/intravitreal injection of triamcinolone acetonide
C-IVC/C-IVTA:intravitreal injection of conbercept/intravitreal injection of triamcinolone acetonide

Sponsors

The second Hospital of Dalian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Foveal center-involved macular edema associated with BRVO or CRVO on clinical examination; CRT >=250 um; 2. Aged between 18 to 80 years; Good behavior and understanding capability to comply with examination and treatment; 3. BCVA (ETDRS letter score) <=70; 4. No refractive media opacity affects the fundus examination; the diameter of the pupil can be dilated to at least 6 mm; 5. Blood pressure (BP) can be controlled under 150/90 mmHg; fasting blood glucose can be controlled under 10 mmol/L; 6. Normal systemic examinations, including blood routine examination, coagulation function.

Exclusion criteria

Exclusion criteria: 1. Pregnant and lactating women; individuals simultaneously participating in any other clinical trial; 2. Macular edema due to a cause other than RVO;Glaucoma, IOP > 25 mmHg; optic atrophy; uveitis; 3. Active inflammation in the eyeball or ocular adnexal region; 4. FFA shows non-perfusion (NP) area more than five optic disks area(BRVO)or ten optic disks area(CRVO) or neovascularization on the retina; 5. Prior treatment with any anti-VEGF treatment or local or systemic corticosteroid use within 6 months before randomization; 6. History of intraocular surgery, history of grid macular photocoagulation (GMP), panretinal photocoagulation (PRP),or iridotomy before randomization; 7. Pseudophakic eye or aphakic eye.

Design outcomes

Primary

MeasureTime frame
best corrected visual acuity;central retinal thickness;—

Secondary

MeasureTime frame
average injection number;average injection interval;—

Countries

China

Contacts

Public ContactFei Liu

The second Hospital of Dalian Medical University

drliufei@dmu.edu.cn+86 17709872593

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026